Asianet Newsable · Healthcare · 2026-08-21
SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing
The company said it has, in accordance with FDA guidance, removed Catalent Indiana—a fill-finish plant now owned by Novo Nordisk—from its U.S. biologics license application for apitegromab.
Read original on Asianet Newsable Get the app
Licensed summary · LicensedSummary
Related briefs
- Health 360: Maharashtra FDA cracks down on surrogate ads, unhealthy dining risks
- Background logic for FDA arguments to mandate folic acid fortification – Sanjeev Sabhlok blog
- CAPR Stock Sinks As Investors Brace For Imminent FDA Call On Deramiocel
- Flies, cockroaches, stale food: FDA suspends licences of several Maharashtra outlets
- 5,414 Fined For Entering Divyangjan Coaches On Western Railway As Activists Demand Stricter Checks